Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced the results of its 2025 first extraordinary general meeting, where several resolutions were voted on. Key stakeholders, including directors and major shareholders, abstained from voting on resolutions related to the A Share Option Scheme, H Share RSU Scheme, and other agreements due to their material interests, ensuring compliance with governance practices.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, focusing on the pharmaceutical industry. It is involved in the research, development, manufacturing, and distribution of pharmaceutical products, with a significant presence in both domestic and international markets.
Average Trading Volume: 10,784,167
Technical Sentiment Signal: Buy
Current Market Cap: HK$81B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.